Bear Creek Capital -Tonix Pharmaceuticals Holding Corp-Sarasota Dinner

1111 Ritz Carlton Drive,Sarasota FL 34236

07 May, 2021

Description

Come learn more about Tonix Pharaceuticals Holding Corp. (NASDAQ: TNXP) and their management team. *Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration. Bear Creek Capital Presents:Dinner & Corporate PresentationTonix Pharmaceuticals Holding Corp (NASDAQ:  TNXP)Friday, May 7, 2021Jack Dusty1111 Ritz-Carlton DriveSarasota, FL 34236Promptly at 5:30 PMJoin Tonix Pharaceuticals Holding Corp. Co-Founder, CEO & Chairman Seth Lederman for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. We hope you can join our presentation About Tonix Pharmaceuticals Holding Corp.Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the second quarter of 20212 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox. 1TNX-102 SL is an investigational new drug and has not been approved for any indication. 2Pending submission and agreement from FDA on statistical analysis plan. 3TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication. In the NewsTonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2 Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm) Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions Presentation Format:  5:30 p.m. to 7:00 p.m. – Presentation and Dinner Contact: Raymond Oliver CEO, Bear Creek Capital 321-439-2120 [email protected]